Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Immunology
Zemi Dossier
Research-use only
Cell Therapy for Autoimmune Disease
A decision package on whether autoimmune cell-therapy responses can become durable immune reset rather than temporary depletion or case-report momentum.
Decision this dossier helps answer
Which autoimmune cell-therapy programs have a credible durability path, and what would reveal relapse risk before scale-up?
Problem this dossier solves
The core question is not whether response is possible; it is whether reset lasts.
The dossier evaluates autoimmune cell therapy through relapse mechanics: where autoreactive biology hides, how immune reconstitution rebuilds risk, and what evidence would show durable reset before buyers extrapolate from early response.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
102-page research report plus 41-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
The core question is not whether response is possible; it is whether reset lasts.
The dossier evaluates autoimmune cell therapy through relapse mechanics: where autoreactive biology hides, how immune reconstitution rebuilds risk, and what evidence would show durable reset before buyers extrapolate from early response.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual Cell Therapy for Autoimmune Disease research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Table of Contents | Shows the report structure and where to inspect the argument, evidence, workbook logic, and limits. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 1. Report Scope & Evidence Integrity Statement | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| 2. Claim Boundary & FDA-Category Discipline | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| 3. 2026 Translational Signal Update & Evidence Refresh Addendum | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Lets the buyer audit support strength before relying on the package. |
| 3.5. The June 2026 Frontier — the Current Landscape (outside-in) | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 3.6. What the June 2026 Frontier Forces — Three Discovery-Grade Reframes | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 3b. Decision Brief: Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 4. Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 5. Decision Snapshot | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 6. Buyer Decision Cheat Sheet (by platform AND indication) | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 7. Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| 8. The Persistence × Sanctuary × Reconstitution Model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 8a. The Reset-Durability Index — making the bottleneck measurable | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| 8b. The Reset-Durability Classifier — operationalizing the thesis as a decision tool | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| 8c. Applying the Reset-Durability Classifier — worked examples | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| 9. Platform Comparison & Evidence Maturity Matrix (modality-level) | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| 10. Relapse-Mode Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 11. Key Findings & Quantitative Evidence | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Lets the buyer audit support strength before relying on the package. |
| 11b. Quantitative evidence — interpretation, confidence, and what each number does not establish | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Lets the buyer audit support strength before relying on the package. |
| 12. Mechanistic Insights | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 12c. The three-compartment model in depth — circulation, lymphoid tissue, parenchyma | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 13. Safety: CRS, ICANS, Infection, Secondary Malignancy, Cytopenia, GvHD | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| 13b. Safety, signal by signal — a diligence-grade treatment | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| 14. Durability & Indication Gradient | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 14b. Durability by indication — the reset gradient in detail | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 15. Persistence & Antigen Dynamics | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 16. Manufacturing, Scalability & CMC | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 16b. The biomarker-to-endpoint bridge and the surrogate gap | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| 16c. Patient selection and stratification — who resets, and how to tell in advance | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 17. Regulatory Pathway & Classification | Explains which biological signals matter for interpreting the field and discriminating between programs. | Shows where the thesis could fail or require more validation before action. |
| 17b. Endpoint and regulatory-science considerations | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| 18. Indication-Specific Deep Dives | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 19. Oncology ↔ Autoimmune Cross-Domain Translation | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 19b. Cross-Domain Synthesis — Five Non-Obvious Connections | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 19c. Clinical and Translational Implications by Stakeholder | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 19d. Three Further Cross-Domain Connections | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | 1 Workbook Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Hypotheses, 15: 5 Flagship + 5 Frontier + 5. fields and clipped entries such as Executable modules, RDC classifier. |
| 2 | 2 Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes claim_id, claim_label, claim_text, report_section fields and clipped entries such as K001, Finding 1 — CD19-directed CAR-T cell.,. |
| 3 | 2b Appendix-Only Claims | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes claim_id, claim_label, claim_text, report_section fields and clipped entries such as K029, Finding 29 — PP2A controls., PP2A. |
| 4 | 3 Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes identifier, title, authors, journal fields and clipped entries such as PMID:41962541, CD19 CAR-T therapy induces remission., Korte IK, Kharboutli. |
| 5 | 4 Source Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes claim_label, primary_citation, resolves, verdict fields and clipped entries such as Finding 1 — CD19-directed CAR-T cell., PMID:41962541, True. |
| 6 | 5 Source Quality Summary | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes Audited claims (original pack), 335 fields and clipped entries such as Currency-add (verified 2026-06-13), Audited total. |
| 7 | 6 Evidence Maturity Matrix | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes Modality, Human AI evidence, Persistence data, Sanctuary reach fields and clipped entries such as Autologous CD19 CAR-T, Drug-free remission.,. |
| 8 | 7 Platform Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Platform, Highest human AI evidence, Persistence, Sanctuary reach fields and clipped entries such as CD19 CAR-T, Drug-free remission., 4-1BB. |
| 9 | 8 Indication Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Indication, Best evidence, Named index, Reset-favorability fields and clipped entries such as SLE / lupus nephritis, ICG318 10/12 sCR;. |
| 10 | 9 PSR Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Axis, What it governs, Best current evidence, Key bottleneck fields and clipped entries such as Persistence, Depth/duration of depletion, 4-1BB vs. |
| 11 | 10 Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes figure_id, figure_title, figure_family, section_anchor fields and clipped entries such as fig01_hero, Persistence x Sanctuary x.,. |
| 12 | 11 Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes figure_id, attempt_status, engine, publishability fields and clipped entries such as fig01_hero, RENDERED, Grok. |
| 13 | 12 Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes ID, Tier, Paradigm, Axis / title fields and clipped entries such as F1, Flagship, F1 - The naive:memory reconstitution.. |
| 14 | 13 Most Valuable Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes study_id, study_title, research_question, hypothesis_tested fields and clipped entries such as NS1, Randomized Ph2 NMOSD: CD19 vs BCMA.,. |
| 15 | 14 Validation-Falsification | Connects proposed validation work to falsification criteria, readouts, and decision gates. Public preview exposes gate_id, thesis_element, what_confirms, what_weakens fields and clipped entries such as G1-Reconstitution, Reconstitution quality governs.,. |
| 16 | 15 Safety Tracker | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes Signal, Observed in AI cohorts, Severity context, Source/Note fields and clipped entries such as Secondary T-cell malignancy, Not yet reported in AI. |
| 17 | 16 Manufacturing-CMC Matrix | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Modality, Vein-to-vein, Key advantage, Key risk fields and clipped entries such as Autologous standard, 3-4 weeks, Established. |
| 18 | 17 Biomarker-Endpoint Tracker | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. Public preview exposes 17 Biomarker-Endpoint Tracker fields from this sheet. |
| 19 | 18 Regulatory Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes Item, Status/Detail fields and clipped entries such as Autoimmune approval (any cell therapy), NONE (all investigational), Approved. |
| 20 | 19 Trial-Registry Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes NCT, Title, Sponsor, Phase fields and clipped entries such as NCT04146051, Descartes-08 CAR-T Cells in., Cartesian Therapeutics. |
| 21 | 20 External 2026 Update Sources | Monitoring surface for emerging signals, update triggers, and evidence changes that could alter the decision. Public preview exposes Category/date, Asset/ID, Finding, Thesis impact fields and clipped entries such as 2026-06-04 regulatory,. |
| 22 | 21 Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as F1, NS2, naive:memory ratio predicts 12-mo.. |
| 23 | RDC_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness, fraction of the above actually., ____ fields and clipped entries such as Reset-favorable threshold, weighted-risk level. |
| 24 | RDC_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Axis (limiting-mode class), Meaning (rubric: 3 = severe., Risk 0-3 (ENTER), Weight (expert-init) fields and clipped entries such as. |
| 25 | RDC_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype (risk scores P/Sm/St/R), Dominant axis, Confidence, OUTPUT CLASS (tissue-resolved at. fields and clipped entries such as. |
| 26 | RDC_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Class (rate-limiting relapse mode), Recommended strategy, Primary functional endpoint, Required safety readout fields and clipped entries such as. |
| 27 | RDC_Indication_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Target organ (tissue node), Tissue-matched strategy, Contraindication, Safety flag (rescue=risk) fields and clipped entries such as SSc-ILD,. |
| 28 | RDC_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Named clinical-index response., Endpoint, Required fields from this sheet. |
| 29 | RDC_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype, Profile (risk P/Sm/St/R + organ), Binding class, Matched move fields and clipped entries such as Persistence-limited (Jo-1-like),. |
| 30 | RDC_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Held-out AUC target, >= 0.80 (the reconstitution axis;. fields and clipped entries such as Failure threshold, Held-out AUC < 0.80, OR the RDC. |
| 31 | RDC_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes RDC element, Maps to claim/finding, Evidence ID, Figure fields and clipped entries such as Persistence axis, exhaustion/anti-CAR/re-dose. |
| 32 | Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes claim_id, report_section, report_page, claim_text fields and clipped entries such as K001, Clinical & Translational Implications, PDF. |
| 33 | Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes Competitive axis-fit / maturity., ordinal bubble, Expert placement of each program., YES (expert) fields and clipped entries such as Buyer. |
| 34 | Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset/platform, Modality, RDC axis-fit fields and clipped entries such as Kyverna, KYV-101 / miv-cel, Auto CD19 (fully-human binder). |
| 35 | Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes v1.x (base), 2026-06-04, Original RELEASE-READY build., prior build fields and clipped entries such as Model, Reset-Durability v2.0,. |
| 36 | Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes #, Issue, Status, Resolution fields and clipped entries such as AI-1, Workbook genuinely executable., RESOLVED. |
| 37 | Excluded Claims | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes bucket, claim_label, score, primary_citation fields and clipped entries such as beyond-capacity, Excluded 279 — Regulatory T. |
| 38 | Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Whole dossier (2026-06-04 build), ELEVATE (preserve+build), Preserved verified base (thesis,. fields and clipped entries such as. |
| 39 | Verification-Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes Database / pass, Query, Hits, Window fields and clipped entries such as 2026-06-04 base, multi-db, Original verification +.. |
| 40 | Expert Review-Validation | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes Attestation item, Status fields and clipped entries such as Original report + verified base., YES (thesis, anchors, figures,., Fresh scan to 2026-06-13. |
| 41 | Gate Compliance Ledger | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Gate, Requirement, Evidence, Status fields and clipped entries such as G0, Read sources not claim-text, Verified base preserved; fresh.. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| F1 | naive:memory ratio predicts 12-mo relapse (discrimination) | AUC (Hanley-McNeil, external) | 0.8 | 0.05 | 0.80 | 7 | 120 |
| F2 | 12-mo drug-free remission (axis-matched vs best-single-axis) | two-proportion, pooled | 0.6 | 0.05 | 0.80 | 62 | 62 |
| F3 | 12-mo medication-free DORIS CR (BCMA salvage vs CD19 reinfusion) | two-proportion, pooled | 0.6 | 0.05 | 0.80 | 42 | 42 |
| F4 | organ-specific progression: Trm-high vs Trm-low | two-proportion, pooled | 0.55 | 0.05 | 0.80 | 29 | 29 |
| F5 | naive-biased reconstitution rate (no-LD vs LD) | two-proportion, pooled | 0.65 | 0.05 | 0.80 | 62 | 62 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 102-page report + 41-sheet workbook
Buy now
- Decision research report (102 pages, PDF)
- Evidence & Decision Workbook (41 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price